172 related articles for article (PubMed ID: 27404034)
1. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials.
Gallagher JC; Palacios S; Ryan KA; Yu CR; Pan K; Kendler DL; Mirkin S; Komm BS
Menopause; 2016 Oct; 23(10):1083-91. PubMed ID: 27404034
[TBL] [Abstract][Full Text] [Related]
2. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
3. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
[TBL] [Abstract][Full Text] [Related]
4. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
6. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
7. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.
Palacios S; Mejía Ríos A
Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066
[TBL] [Abstract][Full Text] [Related]
10. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
12. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.
Stevenson JC; Chines A; Pan K; Ryan KA; Mirkin S
J Clin Endocrinol Metab; 2015 Jun; 100(6):2329-38. PubMed ID: 25894963
[TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629
[TBL] [Abstract][Full Text] [Related]
14. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.
Pinkerton JV; Pickar JH; Ryan KA; Yu CR; Mirkin S; Komm BS
Menopause; 2016 Jun; 23(6):611-20. PubMed ID: 27163519
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
16. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
17. Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.
Kagan R; Komm BS; Ryan KA; Lavenberg J; Yu CR; Pinkerton JV
Menopause; 2016 Nov; 23(11):1204-1213. PubMed ID: 27433860
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial.
Palacios S; Williams R; Mirkin S; Pan K; Arias L; Komm BS
Menopause; 2016 Jul; 23(7):771-7. PubMed ID: 27116464
[TBL] [Abstract][Full Text] [Related]
19. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
20. Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.
Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
Menopause; 2017 Dec; 24(12):1372-1377. PubMed ID: 28609389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
